**RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)**

**Background:** In early 2020, as this protocol was being developed, there were no approved treatments for COVID-19, a disease induced by the novel coronavirus SARS-CoV-2 that emerged in China in late 2019. The UK New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) advised that several possible treatments should be evaluated, including Lopinavir-Ritonavir, low-dose corticosteroids, and Hydroxychloroquine (which has now been done). A World Health Organization (WHO) expert group issued broadly similar advice. These groups also advised that other treatments would soon emerge that require evaluation. In addition, due to lack of community transmission due to COVID-19 control measures, a more severe influenza season is expected when these ease.

**Eligibility and randomisation:** This protocol describes a randomised trial among patients hospitalised for COVID-19 and/or influenza. (Treatments for influenza are only being assessed in the UK.) Eligible patients are randomly allocated between one or more treatment arms, each to be given in addition to the usual standard of care in the participating hospital. The study is dynamic, and treatments are added and removed as results and suitable treatments become available. The randomised treatment comparisons in this version of the protocol (which should be checked and confirmed as the current version) are shown in Table 1. .

|  |  |  |  |
| --- | --- | --- | --- |
| **Condition** | **Randomised comparisons,**  **each vs. usual care alone** | **UK** | **Other countries** |
| COVID-19 | High-dose  corticosteroids | ✓  (age ≥18 years  with hypoxia)a | ✓  (age ≥18 years  with hypoxia)a |
|  | Empagliflozin | ✓  (age ≥18 years) | ✓  (age ≥18 years) |
|  | Sotrovimab | ✓  (age ≥12 years) | 🗶 |
| Molnupiravir | ✓  (age ≥18 years) | ✓  (age ≥18 years) |
| Paxlovid | ✓  (age ≥18 years) | 🗶 |
| Influenza | Baloxavir | ✓  (age ≥12 years) | 🗶 |
| Oseltamivir | ✓  (any age) | 🗶 |
| Low-dose  corticosteroids | ✓  (any age with hypoxia)b | 🗶 |
| a without suspected or confirmed influenza infection; b without suspected or confirmed SARS-CoV-2 infection. Information on completed arms is available in Section 7. | | | |

**Table 1: Current comparisons**

In a partial factorial design, participants may be entered into one or more randomised comparisons of active treatment plus usual care vs. usual care alone, simultaneously. This allows the effects of one treatment to be assessed in the presence or absence of another which generates useful information for clinicians and health policy-makers. In particular, this allows antiviral therapies to be assessed as monotherapy and in combination, which will provide important information on the efficacy, safety and the development of resistance. This protocol indicates clearly where specific combinations are not desirable.

**Adaptive design:** The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The most important task for the DMC will be to assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. Regardless, follow-up will continue for all randomised participants, including those previously assigned to trial arms that are modified or ceased. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.

**Outcomes:** The main outcomes will be death, discharge, need for ventilation and need for renal replacement therapy. For the main analyses, follow-up will be censored at 28 days after randomisation. Additional information on longer term outcomes may be collected through review of medical records or linkage to medical databases where available (such as those managed by NHS Digital and equivalent organisations in the devolved nations).

**Simplicity of procedures:** To facilitate collaboration, even in hospitals that suddenly become overloaded, patient enrolment (via the internet) and all other trial procedures are greatly streamlined. Informed consent is simple and data entry is minimal. Randomisation via the internet is simple and quick, at the end of which the allocated treatment is displayed on the screen and can be printed or downloaded. Key follow-up information is recorded at a single timepoint and may be ascertained by contacting participants in person, by phone or electronically, or by review of medical records and databases.

**Data to be recorded:** At randomisation, information will be collected on the identity of the randomising clinician and of the patient, age, sex, major co-morbidity, pregnancy, illness onset date and severity, and any contraindications to the study treatments. The main outcomes will be death (with date and probable cause), discharge (with date), need for ventilation (with number of days recorded) and need for renal replacement therapy. Reminders will be sent if outcome data have not been recorded by 28 days after randomisation. Suspected Unexpected Serious Adverse Reactions (SUSARs) to one of the study medications (e.g., Stevens-Johnson syndrome, anaphylaxis, aplastic anaemia) will be collected and reported in an expedited fashion. Other adverse events will not be recorded but may be available through linkage to medical databases.

**Numbers to be randomised:** The larger the number randomised the more accurate the results will be, but the numbers that can be randomised will depend critically on how large the epidemic becomes. If substantial numbers are hospitalised in the participating centres then it may be possible to randomise several thousand with mild disease and a few thousand with severe disease, but realistic, appropriate sample sizes could not be estimated at the start of the trial.

**Heterogeneity between populations:** If sufficient numbers are studied, it may be possible to generate reliable evidence in certain patient groups (e.g. those with major co-morbidity or who are older). To this end, data from this study may be combined with data from other trials of treatments for COVID-19 or influenza.

**Add-on studies:** Particular countries or groups of hospitals, may well want to collaborate in adding further measurements or observations, such as serial blood gases or chemistry, serial lung imaging, or serial documentation of other aspects of disease status. While well-organised additional research studies of the natural history of the disease or of the effects of the trial treatments could well be valuable (although the lack of placebo control may bias the assessment of subjective side-effects, such as gastro-intestinal problems), they are not core requirements.

**To enquire about the trial, contact the RECOVERY Central Coordinating Office**

Nuffield Department of Population Health, Richard Doll Building, Old Road Campus,

Roosevelt Drive, Oxford OX3 7LF, United Kingdom

Tel: 0800 1385451 | E-mail: [recoverytrial@ndph.ox.ac.uk](mailto:recoverytrial@ndph.ox.ac.uk) | Website: [www.recoverytrial.net](http://www.recoverytrial.net)

**To enquire about the trial outside of the UK, contact the relevant Clinical Trial Units**

**To RANDOMISE a patient, visit:** [**www.recoverytrial.net**](file:///\\wincluster1dfs\K\NPEUDATA\Current%20trials\RECOVERY\Trial%20Management\Protocol%20-%20latest\V14.0%20development\www.recoverytrial.net)

1 BACKGROUND AND RATIONALE 5

1.1 Setting 5

1.2 Treatment Options 5

1.3 Modifications to the number of treatment arms 5

1.4 Design Considerations 6

1.5 Potential for effective treatments to become available 6

1.6 Early phase assessments 7

2 Design and Procedures 7

2.1 Eligibility 7

2.2 Consent 8

2.3 Baseline information 9

2.4 Randomised allocation of treatment for COVID-19 9

2.5 Randomised allocation of treatment for influenza (UK only) 11

2.6 Administration of allocated treatment 12

2.7 Collecting follow-up information 12

2.8 Duration of follow-up 13

2.9 Withdrawal of consent 14

3 Statistical analysis 14

3.1 Outcomes 14

3.2 Methods of analysis 15

4 DATA and saFETy Monitoring 16

4.1 Recording Suspected Serious Adverse Reactions 16

4.2 Central assessment and onward reporting of SUSARs 16

4.3 Recording other Adverse Events 17

4.4 Role of the Data Monitoring Committee (DMC) 17

4.5 Blinding 17

5 Quality Management 18

5.1 Quality By Design Principles 18

5.2 Training and monitoring 18

5.3 Data management 19

5.4 Source documents and archiving 19

6 Operational and administrative details 19

6.1 Sponsor and coordination 19

6.2 Funding 20

6.3 Indemnity 20

6.4 Local Clinical Centres 20

6.5 Supply of study treatments 20

6.6 End of trial 20

6.7 Publications and reports 21

6.8 Substudies 21

7 VERSION HISTORY 22

8 Appendices 24

8.1 Appendix 1: Information about the treatment arms 24

8.2 Appendix 2: Drug specific contraindications and cautions 28

8.3 Appendix 3: Paediatric dosing information 32

8.4 Appendix 4: Use of IMPs in pregnant and breastfeeding women 34

8.5 Appendix 5: Organisational Structure and Responsibilities 36

9 REFERENCES 38

10 Contact details 41

1. BACKGROUND AND RATIONALE

## Setting

In 2019 a novel coronavirus-disease (COVID-19) emerged in Wuhan, China. A month later the Chinese Center for Disease Control and Prevention identified a new beta-coronavirus (SARS coronavirus 2, or SARS-CoV-2) as the aetiological agent.[1](#_ENREF_1) The clinical manifestations of COVID-19 range from asymptomatic infection or mild, transient symptoms to severe viral pneumonia with respiratory failure. As many patients do not progress to severe disease the overall case fatality rate per infected individual is low, but hospitals in areas with significant community transmission have experienced a major increase in the number of hospitalised pneumonia patients, and the frequency of severe disease in hospitalised patients can be as high as 30%.[2-4](#_ENREF_2) The progression from prodrome (usually fever, fatigue and cough) to severe pneumonia requiring oxygen support or mechanical ventilation often takes one to two weeks after the onset of symptoms.[2](#_ENREF_2) The kinetics of viral replication in the respiratory tract are not well characterized, but this relatively slow progression provides a potential time window in which antiviral therapies could influence the course of disease. In May 2020 a new COVID-associated inflammatory syndrome in children was identified, Paediatric Inflammatory Multisystem Syndrome - Temporally associated with SARS-CoV-2 (PIMS-TS).[5](#_ENREF_5) A rapid NHS England-led consensus process identified the need to evaluate corticosteroids and intravenous immunoglobulin (IVIg) as initial therapies in PIMS-TS, and confirmed tocilizumab as one of the biological anti-inflammatory agents to be evaluated as a second line therapy.

The COVID-19 control measures in place in the UK during the winter of 2020/21 resulted in an almost complete absence of influenza transmission over that period. This extended period without exposure to influenza viruses is unique and may have resulted in antibody waning and increased population susceptibility. Therefore, there is a possibility of a large resurgence of influenza in the winter of 2021/22. The treatment of influenza in hospitalised patients has progressed little in the last 20 years and there is substantial uncertainty and disagreement about optimal treatment of this patient group.

## Treatment Options

The protocol allows reliable assessment of the effects of multiple different treatments (including re-purposed and novel drugs) on major outcomes in COVID-19, influenza and PIMS-TS. All patients will receive usual care for the participating hospital. The current treatments under evaluation are summarised in Table 1 above with further details provided in sections 2.4-2.6 and in Appendices 1-4 (sections 8.1-8.4).

## Modifications to the number of treatment arms

Other arms can be added if evidence emerges that there are suitable candidate therapeutics. Conversely, in some patient populations, not all trial arms are appropriate (e.g. due to contraindications based on co-morbid conditions or concomitant medication); in some hospitals or countries, not all treatment arms will be available (e.g. due to manufacturing and supply issues); and at some times, not all treatment arms will be active (e.g. due to lack of relevant approvals and contractual agreements). The Trial Steering Committee may elect to pause one or more of the arms in order to increase trial efficiency during a fluctuating epidemic. In any of these situations, randomisation will be between fewer arms. Depending on the availability and suitability of treatments, it may be allowed for participants to be randomised in only one or two parts of the main randomisations.

## Design Considerations

The RECOVERY Protocol describes an overarching trial design to provide reliable evidence on the efficacy of candidate therapies for confirmed COVID-19 and/or influenza infection in hospitalised patients receiving usual standard of care. (Treatments for influenza are only being assessed in the UK.)

In early 2020, when the trial first started, there were no known treatments for COVID-19. The anticipated scale of the epidemic is such that hospitals, and particularly intensive care facilities, may be massively overstretched at some points in time, with around 10% requiring hospitalisation. Similarly, the winter of 2021-22 may pose a similar challenge to hospitals when ongoing COVID-19 cases coincide with a significant number of influenza cases. In such situations, even treatments with only a moderate impact on survival or on hospital resources could be worthwhile. Therefore, the focus of RECOVERY is the impact of candidate treatments on mortality and on the need for hospitalisation or ventilation.

Critically, the trial is designed to minimise the burden on front-line hospital staff working within an overstretched care system during a major epidemic. Eligibility criteria are therefore simple and trial processes (including paperwork) are minimised.

The protocol is deliberately flexible so that it is suitable for a wide range of settings, allowing:

* a broad range of patients to be enrolled in large numbers;
* randomisation between only those treatment arms that are *both* available at the hospital *and* not believed by the enrolling doctor to be contraindicated (e.g. by particular co-morbid conditions or concomitant medications);
* treatment arms to be added or removed according to the emerging evidence; and
* additional substudies may be added to provide more detailed information on side effects or sub-categorisation of patient types but these are not the primary objective and are not required for participation.

In a cohort of 191 hospitalised COVID-19 patients with a completed outcome, the median time from illness onset to discharge was 22.0 days (IQR 18.0-25.0) and the median time to death was 18.5 days (15.0-22.0). Thirty-two patients (17%) required invasive mechanical ventilation and the median time from onset to mechanical ventilation was 14.5 days. Therefore, early endpoint assessment, such as 28 days after randomisation, is likely to provide largely complete outcome data and will permit early assessment of treatment efficacy and safety.[6](#_ENREF_6) For influenza, the average length of hospital stay in the UK is around 9 days, so assessment at 28 days will capture most outcomes.[7](#_ENREF_7)

## Potential for effective treatments to become available

In early 2020, when the trial first started, there were no known treatments for COVID-19. However, over time, effective treatments may become available, typically as the result of reliable information from randomised trials (including from this study). For example, in June 2020, results from the RECOVERY trial showed that dexamethasone 6mg once daily reduces the mortality in COVID-19 patients requiring mechanical ventilation or oxygen. In response, many clinical guidelines now recommend the use of dexamethasone 6mg once daily as standard of care for these types of patients.

The RECOVERY trial randomises eligible participants to usual standard of care for the local hospital alone vs usual standard of care plus one or more additional study treatments. Over time, it is expected that usual standard of care alone will evolve. Thus randomisation will always be relevant to the current clinical situation and the incremental effects of the study treatments will be appropriately assessed.

## Early phase assessments

In the UK, the COVID-19 Therapeutics Advisory Panel (CTAP[[1]](#footnote-2)) may propose that RECOVERY assesses interventions for which additional information is required before they are considered for large-scale assessment of the impact on mortality. Such assessments will be tailored to the uncertainty specific to the intervention and typically be conducted at a subset of sites among a smaller group of participants before the results are reviewed and a decision made whether to include them in the main trial.

1. Design and Procedures

## Eligibility

Patients are eligible for the study if all of the following are true:

1. **Hospitalised**
2. **a) Viral pneumonia syndrome**

In general, viral pneumonia should be suspected when a patient presents with:

1. typical symptoms (e.g. influenza-like illness with fever and muscle pain, or respiratory illness with cough and shortness of breath); and
2. compatible chest X-ray findings (consolidation or ground-glass shadowing); and
3. alternative causes have been considered unlikely or excluded (e.g. heart failure, bacterial pneumonia).

However, the diagnosis remains a clinical one based on the opinion of the managing doctor.

1. **Confirmed SARS-CoV-2 infection (all countries) and/or influenza A or B infection (UK only)**
2. **No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial**

Patients in the UK with SARS-CoV-2 and influenza co-infection are eligible, but would be excluded from certain comparisons (as described in the table on page 1). In addition, if the attending clinician believes that there is a specific contra-indication to one of the active drug treatment arms (see Appendix 2, Appendix 3 [for children], and Appendix 4 for pregnant and breastfeeding women) or that the patient should definitely be receiving one of the active drug treatment arms then that arm will not be available for randomisation for that patient. For patients who lack capacity, an advanced directive or behaviour that clearly indicates that they would not wish to participate in the trial would be considered sufficient reason to exclude them from the trial.

Patients who have been previously recruited into RECOVERY are eligible to be recruited again as long as their previous randomisation was >6 months ago.Patients will not be recruited into the same randomised comparison (e.g. sotrovimab vs. usual care) on more than one occasion, regardless of how far apart they occur.

In some locations, children (aged <18 years) will not be recruited, to comply with local and national regulatory approvals (see Table 1 and Sections 2.4-2.6 and 8.3).

## Consent

Informed consent should be obtained from each patient 16 years and over before enrolment into the study. Due to the poor outcomes in COVID-19 patients who require ventilation (>90% mortality in one cohort[6](#_ENREF_6)), patients who lack capacity to consent due to severe disease (e.g. needs ventilation), and for whom a relative to act as the legally designated representative is not available (in person), randomisation and consequent treatment will proceed with consent provided by a clinician (independent of the trial[[2]](#footnote-4)) who will act as the legally designated representative (if allowed by local regulations).

If they regain capacity, such participants should be provided with information about the trial (ideally prior to discharge, but otherwise as soon as possible thereafter), what their rights are and how to exercise them, but it is not necessary to obtain their written consent[[3]](#footnote-5). Provision of such information (i.e. the current participant information sheet) will be documented in the medical record.

For children aged <16 years old consent will be sought from their parents or legal guardian. Where possible, children aged between 10-15 years old will also be asked for assent. Children aged ≥16 years old will asked for consent as for adults. Witnessed[[4]](#footnote-6) consent may be obtained over the telephone or web video link if hospital visiting rules or parental infection mean a parent/guardian cannot be physically present.

Information about participants’ involvement will be included in routine clinical communications (e.g. discharge summaries) provided to participants (and, in the UK their GPs) . If any other relevant information arises during the trial, this may also be sent to GPs.

## Baseline information

The following information will be recorded on the web-based form by the attending clinician or delegate:

* Patient details (e.g. name or initials [depending on privacy requirements], NHS/CHI number [UK only] or medical records number, date of birth, sex)
* Clinician details (e.g. name)
* Symptom onset date
* Disease severity as assessed by need for supplemental oxygen, non-invasive ventilation or invasive mechanical ventilation/extracorporeal membrane oxygenation (ECMO)
* Oxygen saturations on air (if available)
* Latest routine measurement of creatinine, C-reactive protein, and D-dimer (if available)
* SARS-CoV-2 test result (and/or influenza test result in UK)
* Major co-morbidity (e.g. heart disease, diabetes, chronic lung disease) and pregnancy (including pregnancy test result in all women of child-bearing potential[[5]](#footnote-7))
* Use of relevant medications (e.g. corticosteroids, anti-virals) and prior vaccination
* Date of hospitalisation
* Contraindication to the study treatment regimens (in the opinion of the attending clinician)
* Name of person completing the form

The person completing the form will then be asked to confirm that they wish to randomise the patient and will then be required to enter their name and e-mail address.

### Baseline sample collection (UK only)[[6]](#footnote-8)

#### Participants with COVID-19

Participants with COVID-19 entering sotrovimab, molnupiravir or Paxlovid comparisons should have a serum sample collected **after obtaining consent and prior to randomisation** in which presence of SARS-CoV-2 antigen and antibodies against it may be tested. In addition, a nasal swab should be collected in which the level of SARS-CoV-2 viral RNA (and genotyping for resistance markers) will be measured.

#### Participants with influenza pneumonia

Participants with influenza pneumonia should have a nasal swab collected in which the presence of influenza virus will be measured.

## Randomised allocation of treatment for COVID-19

In addition to receiving usual care, eligible patients with confirmed SARS-CoV-2 infection will be allocated treatment(s) using a central web-based randomisation service (without stratification or minimisation). A factorial design is used such that eligible patients may be randomised simultaneously to one or more of the study treatment arms (depending on location and infection). The doses in this section are for adults (see Appendix 3 for paediatric dosing).

### Randomisation part E

Eligible patients (adult patients ≥18 years old without suspected or confirmed influenza co-infection) and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations <92% on room air) may be randomised in a ratio of 1:1 to one of the arms listed below.

**• No additional treatment[[7]](#footnote-9)**

• High-dose corticosteroids: **dexamethasone 20 mg (base) once daily** by mouth, nasogastric tube or intravenous infusion for 5 days follow by **dexamethasone 10 mg (base) once daily** by mouth, nasogastric tube or intravenous infusion for 5 days. [[8]](#footnote-10),[[9]](#footnote-11)

### Randomisation part F:

Eligible patients (adult patients ≥18 years old) may be randomised in a 1:1 ratio to one of the arms listed below.

**• No additional treatment**

• **Empagliflozin 10 mg once daily** by mouth for 28 days (or until discharge, if earlier). Participants with diabetes allocated empagliflozin should have daily ketone checks while taking the treatment (see Appendix 2 for further details).

### Randomisation part J (UK only):

Eligible patients (patients ≥12 years old) may be randomised in a 1:1 ratio to one of the arms listed below.

**• No additional treatment**

• **Sotrovimab 1000 mg in 100 mL 0.9% sodium chloride or 5% dextrose** by intravenous infusion over 1 hour as soon as possible after randomisation.

### Randomisation part K:

Eligible patients (patients ≥18 years old) may be randomised in a 1:1 ratio to one of the arms listed below.

**• No additional treatment**

• **Molnupiravir 800 mg twice daily** for 5 daysby mouthk.

### Randomisation part L (UK only):

Eligible patients (patients ≥18 years old) may be randomised in a 1:1 ratio to one of the arms listed below.

**• No additional treatment**

• **Paxlovid (nirmatrelvir/ritonavir) 300/100 mg twice daily** for 5 daysby mouthk.

## Randomised allocation of treatment for influenza (UK only)

In addition to receiving usual care, eligible patients with confirmed influenza A or B infection will be allocated treatment(s) using a central web-based randomisation service (without stratification or minimisation). A factorial design is used such that eligible patients may be randomised simultaneously to one or more of the study treatment arms (depending on location and infection). The doses in this section are for adults (see Appendix 3 for paediatric dosing). Study treatments do not need to be continued after discharge from hospital unless otherwise specified.

### Randomisation part G: (UK only)

Eligible patients (≥12 years old with or without SARS-CoV-2 co-infection) may be randomised in a ratio of 1:1 to one of the arms listed below.

* **No additional treatment**
* **Baloxavir marboxil 40mg (or 80mg if weight ≥80kg) once daily** by mouth or nasogastic tube to be given on day 1 and day 4[[10]](#footnote-12).

### Randomisation part H: (UK only)

Eligible patients (any age, with or without SARS-CoV-2 co-infection) may be randomised in a ratio of 1:1 to one of the arms listed below.

* **No additional treatment**
* **Oseltamivir 75mg twice daily** by mouth or nasogastric tube for five daysk,[[11]](#footnote-13).

### Randomisation part I: (UK only)

Eligible patients (any age without suspected or confirmed SARS-CoV-2 infection) and with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturations <92% on room air) may be randomised in a ratio of 1:1 to one of the arms listed below.

* **No additional treatment**
* Low-dose corticosteroids: **Dexamethasone 6mg once daily given** orally or intravenously for ten days or until discharge (whichever happens earliest)[[12]](#footnote-14)

## Administration of allocated treatment

The details of the allocated study treatments will be displayed on the screen and can be printed or downloaded. The hospital clinicians are responsible for prescription and administration of the allocated treatments. The patient’s own doctors are free to modify or stop study treatments if they feel it is in the best interests of the patient without the need for the patient to withdraw from the study (see section 2.10). This study is being conducted within hospitals. Therefore use of medication will be subject to standard medication reviews (typically within 48 hours of enrolment) which will guide modifications to both the study treatment and use of concomitant medication (e.g. in the case of potential drug interactions).

## Collecting follow-up information

The following information will be ascertained at the time of death or discharge or at 28 days after first randomisation (whichever is sooner):

* Vital status (alive / dead, with date and presumed cause of death, if appropriate)
* Hospitalisation status (inpatient / discharged, with date of discharge, if appropriate)
* Use of ventilation (with days of use and type, if appropriate)
* Use of renal dialysis or haemofiltration
* Documented new major cardiac arrhythmia (including atrial and ventricular arrhythmias)
* Major bleeding (defined as intracranial bleeding or bleeding requiring transfusion, endoscopy, surgery, or vasoactive drugs)
* Thrombotic event, defined as either (i) acute pulmonary embolism; (ii) deep vein thrombosis; (iii) ischaemic stroke; (iv) myocardial infarction; or (v) systemic arterial embolism.
* Non-coronavirus / non-influenza infection, categorised by site and putative organism (virus, bacteria, fungus, other)
* Use of any medications included in the RECOVERY trial protocol (including drugs in the same class) or other purported COVID-19 and influenza treatments (e.g. remdesivir, neuraminidase inhibitors)
* Participation in other randomised trials of interventions (vaccines or treatments) for COVID-19 or influenza.
* Metabolic complications: Ketoacidosis; hyperglycaemic hyperosmolar state; hyperglycaemia requiring new use of insulin; severe hypoglycaemia (defined as hypoglycaemia causing reduced conscious level requiring another person to help recover)
* Seizures
* Laboratory results: highest creatinine, alanine (or aspartate) transamine and bilirubin recorded during admission
* Infusion reactions to Sotrovimab
* For pregnant women in UK, ID number in UK Obstetric Surveillance System

Follow-up information is to be collected on all study participants, irrespective of whether or not they complete the scheduled course of allocated study treatment. Study staff will seek follow-up information through various means including medical staff, reviewing information from medical notes, routine healthcare systems, and registries.

For all randomised participants, vital status (alive / dead, with date and presumed cause of death, if appropriate) is to be ascertained at 28 days after first randomisation. This may be achieved through linkage to routine death registration data (e.g. in the UK) or through direct contact with the participant, their relatives, or medical staff and completion of an additional follow-up form. Where available, data from routine healthcare records (including linkage to medical databases held by organisations such as NHS Digital in the UK) will be used to supplement data collected by trial sites. Further details are described in the [Definition and Derivation of Baseline Characteristics and Outcomes](https://www.recoverytrial.net/files/recovery-outcomes-definitions-v3-0.pdf) standard operating procedure.[[13]](#footnote-16)

### Follow-up swab samples (UK only)[[14]](#footnote-17)

#### Participants with COVID-19

Participants with COVID-19 in sotrovimab, molnupiravir or Paxlovid comparisons should have a nasal swab collected on days 3 and 5 in which the level of SARS-CoV-2 viral RNA (and genotyping for resistance makers) will be measured.

#### Participants with influenza pneumonia

Participants with influenza pneumonia should have a nasal swab collected on day 5 in which the presence of influenza virus (and genotyping for baloxavir or oseltamivir resistance markers) will be measured.

## Duration of follow-up

All randomised participants are to be followed up until death, discharge from hospital or 28 days after randomisation (whichever is sooner). It is recognised that in the setting of this trial, there may be some variability in exactly how many days after randomisation, information on disease status is collected. This is acceptable and will be taken account of in the analyses and interpretation of results, the principle being that some information about post-randomisation disease status is better than none.

In the UK, longer term (up to 10 years) follow-up will be sought through linkage to electronic healthcare records and medical databases including those held by NHS Digital, Public Health England and equivalent bodies, and to relevant research databases (e.g. UK Biobank, Genomics England). Outside the UK, due to the absence of electronic health data linkage, additional follow-up will be conducted at 6 months after first randomisation by telephone or in person (at a clinic) in order to collect information on mortality (including date and cause) and re-admission to hospital (including date[s] and primary reason[s]). This information will be captured on a web-based case report form.

## Withdrawal of consent

A decision by a participant (or their parent/guardian) that they no longer wish to continue receiving study treatment should **not** be considered to be a withdrawal of consent for follow-up. However, participants (or their parent/guardian) are free to withdraw consent for some or all aspects of the study at any time if they wish to do so. In accordance with regulatory guidance, de-identified data that have already been collected and incorporated in the study database will continue to be used (and any identifiable data will be destroyed).

For participants who lack capacity, if their legal representative withdraws consent for treatment or methods of follow-up then these activities would cease. If such participants regain capacity and no longer wish to participate then they can withdraw the consent given on their behalf as above.

1. Statistical analysis

All analyses for reports, presentations and publications will be prepared by the coordinating centre at the Nuffield Department of Population Health, University of Oxford. A more detailed statistical analysis plan will be developed by the investigators and published on the study website whilst still blind to any analyses of aggregated data on study outcomes by treatment allocation.

## Outcomes

### Primary and secondary outcomes for evaluation of potential treatments for COVID-19

For each pairwise comparison with the ‘no additional treatment’ arm, the **primary objective** is to provide reliable estimates of the effect of study treatments on all-cause mortality at 28 days after randomisation (with subsidiary analyses of cause of death and of death at various timepoints following discharge).

The **secondary objectives** are to assess the effects of study treatments on (a) duration of hospital stay (time to discharge alive within the first 28 days); and, (b) among patients not on invasive mechanical ventilation at baseline, the composite endpoint of death or need for invasive mechanical ventilation or ECMO.

### Primary and secondary outcomes for evaluation of potential treatments for influenza

For each pairwise comparison with the ‘no additional treatment’ arm, the **co-primary objectives** are to provide reliable estimates of the effect of study treatments on (a) all-cause mortality at 28 days after randomisation (with subsidiary analyses of cause of death and of death at various timepoints following discharge) and (b) time to discharge alive from hospital. Holm’s procedure will be used to control the family-wise error rate across these two co-primary outcomes at 5%.[8](#_ENREF_8)

The **secondary objective** is to assess the effects of study treatments on the composite endpoint of death or need for invasive mechanical ventilation or ECMO among patients not on invasive mechanical ventilation at baseline.

### Other outcomes for evaluation of all treatments

Other objectives include the assessment of the effects of study treatments on the need for any ventilation (and duration of invasive mechanical ventilation), acute kidney injury and renal replacement therapy, and thrombotic events. Safety outcomes include bleeding, new major cardiac arrhythmias, metabolic complications (ketoacidosis, hyperglycaemic hyperosmolar state, hyperglycaemia requiring new use of insulin, severe hypoglycaemia). Virological outcomes include viral RNA levels in the nasopharynx and the frequency of detection of resistance markers.

Study outcomes will be assessed based on data recorded up to 28 days and up to 6 months after randomisation.

Where available, data from routine healthcare records (including linkage to medical databases held by organisations such as NHS Digital in the UK) and from relevant research studies (such as UK Biobank, Genomics England, ISARIC-4C, the UK Obstetric Surveillance System and PHOSP-COVID) will allow subsidiary analyses of the effect of the study treatments on particular non-fatal events (e.g. ascertained through linkage to Hospital Episode Statistics), the influence of pre-existing major co-morbidity (e.g. diabetes, heart disease, lung disease, hepatic insufficiency, severe depression, severe kidney impairment, immunosuppression), the maternal and infant outcomes in women pregnant at randomisation, and longer-term outcomes as well as in particular sub-categories of patient (e.g. by genotype, pregnancy).

## Methods of analysis

For all outcomes, comparisons will be made between all participants randomised to each treatment and its control, irrespective of whether they received their allocated treatment (“intention-to-treat” analyses).

For time-to-event analyses, each treatment group will be compared with the no additional treatment group using the log-rank test. Kaplan-Meier estimates for the time to event will also be plotted (with associated log-rank p-values). The log-rank ‘observed minus expected’ statistic (and its variance) will be used to estimate the average event rate ratio (and its confidence interval) for those allocated to each treatment group versus the no additional treatment group. For the primary outcome, participants discharged before 28 days will, in the absence of information to the contrary, be assumed to have survived for 28 days. For binary outcomes where the timing of the event is unknown, the risk ratio and its 95% confidence interval (and associated p-value) will be reported.

Pairwise comparisons within each randomisation will be made between each treatment arm and the no additional treatment arm (reference group) in that particular randomisation. However, since not all treatments may be available or suitable for all patients, those in the no additional treatment arm will only be included in a given comparison if, at the point of their randomisation, they *could* alternatively have been randomised to the active treatment of interest. All p-values will be 2-sided.

Pre-specified subgroup analysis (e.g., level of respiratory support, time since onset of symptoms; sex; age group; ethnicity; use of corticosteroids) will be conducted, with tests for heterogeneity (or trend) performed to assess if the effect in any particular subgroup varies materially from the overall effect. Sensitivity analyses will be conducted among those patients with laboratory confirmed SARS-CoV-2. The effect of each treatment (versus its control) will be assessed in the presence or absence of other relevant treatments the patients may receive either (a) as part of their usual care; or (b) as part of the trial (i.e., other factorial randomisations). Further details will be fully described in the Statistical Analysis Plan.

1. DATA and saFETy Monitoring

## Recording Suspected Serious Adverse Reactions

The focus is on those events that, based on a single case, are highly likely to be related to the study medication. Examples include anaphylaxis, Stevens-Johnson Syndrome, or bone marrow failure, where there is no other plausible explanation.

Any Serious Adverse Event[[15]](#footnote-18) that is believed with a reasonable probability to be due to one of the study treatments will be considered a Suspected Serious Adverse Reaction (SSAR). In making this assessment, there should be consideration of the probability of an alternative cause (for example, COVID-19 or influenza itself or some other condition preceding randomisation), the timing of the event with respect to study treatment, the response to withdrawal of the study treatment, and (where appropriate) the response to subsequent re-challenge.

All SSARs should be reported by telephone to the Central Coordinating Office and recorded on the study IT system immediately.

## Central assessment and onward reporting of SUSARs

Clinicians at the Central Coordinating Office are responsible for expedited review of reports of SSARs received. Additional information (including the reason for considering it both serious and related, and relevant medical and medication history) will be sought.

The focus of Suspected Unexpected Serious Adverse Reaction (SUSAR) reporting will be on those events that, based on a single case, are highly likely to be related to the study medication. To this end, anticipated events that are either efficacy endpoints, consequences of the underlying disease, or common in the study population will be exempted from expedited reporting. Thus the following events will be exempted from expedited reporting:

1. Events which are the consequence of COVID-19 or influenza; and
2. Common events which are the consequence of conditions preceding randomisation.

Any SSARs that are not exempt will be reviewed by a Central Coordinating Office clinician and an assessment made of whether the event is “expected” or not (assessed against the relevant Summary of Product Characteristics or Investigator Brochure). Any SSARs that are not expected would be considered a Suspected Unexpected Serious Adverse Reaction (SUSAR).

All confirmed SUSARs will be reported to the Chair of the DMC and to relevant regulatory authorities, ethics committees, and investigators in an expedited manner in accordance with regulatory requirements.

## Recording other Adverse Events

In addition to recording Suspected Serious Adverse Reactions (see section 4.1), information will be collected on all deaths and efforts will be made to ascertain the underlying cause. Other serious or non-serious adverse events will not be recorded unless specified in section 2.8. [[16]](#footnote-19) It is anticipated that for some substudies, more detailed information on adverse events (e.g. through linkage to medical databases) or on other effects of the treatment (e.g. laboratory or radiological features) will be recorded and analysed but this is not a requirement of the core protocol.

## Role of the Data Monitoring Committee (DMC)

During the study, interim analyses of all study data will be supplied in strict confidence to the independent DMC. The DMC will request such analyses at a frequency relevant to the emerging data from this and other studies.

The DMC will independently evaluate these analyses and any other information considered relevant. The DMC will determine if, in their view, the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. Unless this happens, the Trial Steering Committee, Chief Investigator, study staff, investigators, study participants, funders and other partners will remain blind to the interim results until 28 days after the last patient has been randomised for a particular intervention arm (at which point analyses may be conducted comparing that arm with the no additional treatment arm).

The DMC will review the safety and efficacy analyses among children (age <18 years) both separately and combined with the adult data.

## Blinding

This is an open-label study. However, while the study is in progress, access to tabular results of study outcomes by allocated treatment allocation will not be available to the research team, patients, or members of the Trial Steering Committee (unless the DMC advises otherwise).

1. Quality Management

## Quality By Design Principles

In accordance with the principles of Good Clinical Practice and the recommendations and guidelines issued by regulatory agencies, the design, conduct and analysis of this trial is focussed on issues that might have a material impact on the wellbeing and safety of study participants (hospitalised patients with confirmed SARS-CoV-2 or influenza infection) and the reliability of the results that would inform the care for future patients.

The critical factors that influence the ability to deliver these quality objectives are:

* to minimise the burden on busy clinicians working in an overstretched hospital during a major epidemic
* to ensure that suitable patients have access to the trial medication without impacting or delaying other aspects of their emergency care
* to provide information on the study to patients and clinicians in a timely and readily digestible fashion but without impacting adversely on other aspects of the trial or the patient’s care
* to allow individual clinicians to use their judgement about whether any of the treatment arms are not suitable for the patient
* to collect comprehensive information on the mortality and disease status

In assessing any risks to patient safety and well-being, a key principle is that of proportionality. Risks associated with participation in the trial must be considered in the context of usual care.

## Training and monitoring

The focus will be on those factors that are critical to quality (i.e. the safety of the participants and the reliability of the trial results). Remedial actions would focus on issues with the potential to have a substantial impact on the safety of the study participants or the reliability of the results.

The study will be conducted in accordance with the principles of International Conference on Harmonisation Guidelines for Good Clinical Research Practice (ICH-GCP) and relevant local, national and international regulations. Any serious breach of GCP in the conduct of the clinical trial will be handled in accordance with regulatory requirements. Prior to initiation of the study at each Local Clinical Centre (LCC), the Central Coordinating Office (CCO) or relevant Regional Coordinating Centre (RCC) will confirm that the LCC has adequate facilities and resources to carry out the study. LCC lead investigators and study staff will be provided with training materials.

In the context of this epidemic, visits to hospital sites are generally not appropriate as they could increase the risks of spreading infection, and in the context of this trial they generally would not influence the reliability of the trial results or the well-being of the participants. In exceptional circumstances, the CCO or RCC may arrange monitoring visits to LCCs as considered appropriate based on perceived training needs and the results of central statistical monitoring of study data.[9](#_ENREF_9),[10](#_ENREF_10) The purpose of such visits will be to ensure that the study is being conducted in accordance with the protocol, to help LCC staff to resolve any local problems, and to provide extra training focussed on specific needs. No routine source data verification will take place.

## Data management

LCC clinic staff will use the bespoke study web-based applications for study management and to record participant data (including case report forms) in accordance with the protocol. Data will be held in central databases located at the CCO or on secure cloud servers. In some circumstances (e.g. where there is difficulty accessing the internet or necessary IT equipment), paper case report forms may be required with subsequent data entry by either LCC or CCO staff. Although data entry should be mindful of the desire to maintain integrity and audit trails, in the circumstances of this epidemic, the priority is on the timely entry of data that is sufficient to support reliable analysis and interpretation about treatment effects. CCO staff will be responsible for provision of the relevant web-based applications and for generation of data extracts for analyses.

All data access will be controlled by usernames and passwords, and any changes to data will require the user to enter their username and password. Staff will have access restricted to the functionality and data that are appropriate for their role in the study.

## Source documents and archiving

Source documents for the study constitute the records held in the study main database. These will be retained for at least 25 years from the completion of the study. Identifiable data will be retained only for so long as it is required to maintain linkage with routine data sources (see section 2.9), with the exception of children for whom such data must be stored until they reach 21 years old (due to the statute of limitations). The sponsor and regulatory agencies will have the right to conduct confidential audits of such records in the CCO and LCCs (but should mindful of the workload facing participating hospitals and the infection control requirements during this epidemic).

1. Operational and administrative details

## Sponsor and coordination

The University of Oxford will act as the trial Sponsor. The trial will be coordinated by a Central Coordinating Office (CCO) within the Nuffield Department of Population Health staffed by members of the two registered clinical trials units – the Clinical Trial Service Unit and the National Perinatal Epidemiology Unit Clinical Trials Unit. The CCO will oversee Regional Coordinating Centres which will assist with selection of Local Clinical Centres (LCCs) within their region and for the administrative support and monitoring of those LCCs. The data will be collected, analysed and published independently of the source of funding.

## Funding

This study is supported by grants to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and the Wellcome Trust, and by core funding provided by NIHR Oxford Biomedical Research Centre, the Wellcome Trust, the Bill and Melinda Gates Foundation, UK Foreign, Commonwealth and Development Office, Health Data Research UK, NIHR Health Protection Unit in Emerging and Zoonotic Infections and the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.

## Indemnity

The University has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting Management Ltd, at Lloyd’s of London). In the UK, NHS indemnity operates in respect of the clinical treatment that is provided.

## Local Clinical Centres

The study will be conducted at multiple hospitals (LCCs) within each region. At each LCC, a lead investigator will be responsible for trial activities but much of the work will be carried out by medical staff attending patients with COVID-19 within the hospital and by hospital research nurses, medical students and other staff with appropriate education, training, and experience. Where LCCs plan to recruit children the principal investigator will co-opt support from a local paediatrician and/or neonatologists to oversee the management of children and infants in the trial.

## Supply of study treatments

For licensed treatments (e.g. corticosteroids, oseltamivir) all aspects of treatment supply, storage, and management will be in accordance with standard local policy and practice for prescription medications. Treatments issued to randomised participants will be by prescription. Such study treatments will not be labelled other than as required for routine clinical use. They will be stored alongside other routine medications with no additional monitoring. No accountability records will be kept beyond those used for routine prescriptions.

For unlicensed treatments, manufacture, packaging, labelling and delivery will be the responsibility of the pharmaceutical company and, in the UK, the Department of Health and Social Care. Each LCC will maintain an accountability log and will be responsible for the storage and issue of study treatment. If treatments require storage at a specific temperature, LCCs can use existing temperature-controlled facilities and associated monitoring. Treatment issue to randomised participants will be in accordance with local practice (and may be in line with the processes required for routine prescriptions or compassionate use).

Treatment will be issued to randomised participants by prescription.

## End of trial

The end of the scheduled treatment phase is defined as the date of the last follow-up visit of the last participant. In the UK, it is intended to extend follow-up for a year or more beyond the final study visit through linkage to routine medical records and central medical databases. The end of the study is the date of the final data extraction from NHS Digital (anticipated to be 10 years after the last patient is enrolled).

## Publications and reports

The Trial Steering Committee will be responsible for drafting the main reports from the study and for review of any other reports. In general, papers initiated by the Trial Steering Committee (including the primary manuscript) will be written in the name of the RECOVERY Collaborative Group, with individual investigators named personally at the end of the report (or, to comply with journal requirements, in web-based material posted with the report).

The Trial Steering Committee will also establish a process by which proposals for additional publications (including from independent external researchers) are considered by the Trial Steering Committee. The Trial Steering Committee will facilitate the use of the study data and approval will not be unreasonably withheld. However, the Trial Steering Committee will need to be satisfied that any proposed publication is of high quality, honours the commitments made to the study participants in the consent documentation and ethical approvals, and is compliant with relevant legal and regulatory requirements (e.g. relating to data protection and privacy). The Trial Steering Committee will have the right to review and comment on any draft manuscripts prior to publication.

## Substudies

Proposals for substudies must be approved by the Trial Steering Committee and by the relevant ethics committee and competent authorities (where required) as a substantial amendment or separate study before they begin. In considering such proposals, the Trial Steering Committee will need to be satisfied that the proposed substudy is worthwhile and will not compromise the main study in any way (e.g. by impairing recruitment or the ability of the participating hospitals to provide care to all patients under their care).

1. VERSION HISTORY

| Version number | Date | Brief Description of Changes |
| --- | --- | --- |
| 1.0 | 13-Mar-2020 | Initial version |
| 2.0 | 21-Mar-2020 | Addition of hydroxychloroquine. Administrative changes and other clarifications. |
| 3.0 | 07-Apr-2020 | Extension of eligibility to those with suspected COVID-19  Addition of azithromycin arm.  Addition of inclusion of adults who lack permanently lack capacity.  Change to primary outcome from in-hospital death to death within 28 days of randomisation. |
| 4.0 | 14-Apr-2020 | Addition of second randomisation to tocilizumab vs. standard of care among patients with progressive COVID-19. |
| 5.0 | 24-Apr-2020 | Addition of children to study population. |
| 6.0 | 14-May-2020 | Addition of convalescent plasma |
| 7.0 | 18-Jun-2020 | Allowance of randomisation in part B of main randomisation without part A.  Removal of hydroxychloroquine and dexamethasone treatment arms. |
| 8.0 | 03-Jul-2020 | Removal of lopinavir-ritonavir  Addition of intravenous immunoglobulin arm for children  Changes to corticosteroid dosing for children.  Addition of baseline serum sample in convalescent plasma randomisation |
| 9.0 | 10-Sep-2020 | Addition of synthetic neutralizing antibodies  Additional baseline data collection  Addition of countries outside UK |
| 9.1 | 18-Sep-2020 | Addition of information about vaccination of children of pregnant mothers receiving REGN10933+REGN10987 |
| 9.2 [not submitted in UK] | 15-Oct-2020 | Additional information for countries outside UK |
| 10.0 | 26-Oct-2020 | Addition of main randomisation part C  General updates to avoid duplication and improve clarity |
| 10.1 | 01-Nov-2020 | Additional information for pregnant women |
| 11.0 | 19-Nov-2020 | Addition of colchicine to main randomisation part A  Removal of azithromycin from main randomisation part A  Change in randomisation ratio in main randomisation part A from 2:1 to 1:1 |
| 11.1 | 21-Nov-2020 | Clarification of colchicine age thresholds |
| 11.2 [not submitted in UK] | 01-Dec-2020 | Addition of modified aspirin dose if 150mg not available |
| 12.0 | 10-Dec-2020 | Allow second randomisation of children without first randomisation |
| 12.1 | 16-Dec-2020 | Clarification of change in V12.0 |
| 13.0 | 26-Jan-2021 | Addition of baricitinib and anakinra (and change to allocation ratio in second randomisation for children); addition of pregnancy test for women of child-bearing potential (and change to colchicine eligibility);  removal of tocilizumab for adults; removal of convalescent plasma and additional assessment of antibody-based therapy; addition of dexamethasone as substitute if methylprednisolone unavailable |
| 14.0 | 15-Feb-2021 | Addition of Early Phase Assessments; the inclusion of dimethyl fumarate for initial early phase assessment; restriction of main randomisation part B to children with COVID-19 pneumonia; modification of barictinib and tocilizumab co-administration guidance |
| 15.0 | 12-Apr-2021 | Removal of aspirin and colchicine; addition of infliximab and high-dose corticosteroids (ex-UK only) |
| 15.1 [not submitted in UK] | 18-May-2021 | Addition of South Africa |
| 16.0 | 05-Jul-2021 | Removal of REGN-COV2 and main randomisation part B  Removal of infliximab from main randomisation part E (and associated endemic infection monitoring section)  Addition of empagliflozin as main randomisation part F and metabolic outcomes  Addition of India, Sri Lanka and Pakistan |
| V16.1 | 08-Jul-2021 | Clarification of design in introduction |
| V17.0 | 06-Aug-2021 | Addition of additional exclusion criteria and safety monitoring for empagliflozin arm  Removal of corticosteroids and intravenous immunoglobulin in main randomisation part A (for children) |
| V17.1 | 10-Aug-2021 | Clarification of design for children |
| V18.0 | 13-Oct-2021 | Update to consent section  Change in primary outcome and sample size for DMF comparison  Clarification of eligibility for PIMS-TS randomisation  Removal of 3 month follow-up form for non-UK countries |
| V18.1 | 24-Oct-2021 | Clarification of witnesses for consent of children |
| V19.0 | 12-Nov-2021 | Addition of baloxavir marboxil, oseltamivir, and low-dose corticosteroids as randomised comparisons each vs. usual care alone for patients with influenza (in UK only).  Removal of early phase assessment of dimethyl fumarate.  Updated statistical analysis section to align with statistical analysis plan and include influenza analyses. |
| V19.1 | 16-Nov-21 | Clarification of baloxavir and weight eligibility |
| V20.0 | 29-Nov-21 | Removal of baricitinib.  Extension of COVID-19 high-dose corticosteroid and empagliflozin comparisons to other countries. |
| V21.0 | 17-Dec-21 | Addition of sotrovimab and molnupiravir.  Addition of baseline and follow-up samples.  Re-randomisation of patients recruited >6 months ago. |
| V21.1 | 19-Dec-21 | Clarifications post-REC review. |
| V22.0 | 19-Jan-22 | Addition of Paxlovid. (Not implemented.) |
| V23.0 | 08-Mar-22 | Clarifications following MHRA review. UKOSS added to section 3.1.3. Extension of molnupiravir to other countries. Removal of tocilizumab/anakinra for PIMS-TS. |

**Completed comparisons**

The last version of the protocol to include the IMP is shown in the table above.

|  |  |
| --- | --- |
| **IMP** | **Citation** |
| Hydroxycholoroquine | New Engl J Med 2020; 383: 2030-40 |
| Dexamethasone (COVID-19) | New Engl J Med 2021; 384: 693-704 |
| Lopinavir-ritonavir | Lancet 2020; 396: 1345-1352 |
| Azithromycin | Lancet 2021; 397: 605-12 |
| Convalescent plasma | Lancet 2021; 397: 2049-59 |
| Tocilizumab | Lancet 2021; 397: 1637-1645 |
| Aspirin | Lancet 2022; 397: 143-151 |
| Colchicine | Lancet Resp Med 2021; 9: 1419-26 |
| REGN-COV2 | Lancet 2022; 399: 665-76 |
| Methylprednisolone (PIMS-TS) | Analysis ongoing |
| Intravenous immunoglobulin (PIMS-TS) | Analysis ongoing |
| Tocilizumab (PIMS-TS) | Follow-up ongoing |
| Anakinra (PIMS-TS) | Follow-up ongoing |
| Dimethyl fumarate | Analysis ongoing |
| Baricitinib | Medrxiv: 10.1101/2022.03.02.22271623v1 |

1. Appendices

## Appendix 1: Information about the treatment arms

All patients will receive usual care in the participating hospital.

**Corticosteroids:** RECOVERY is assessing the effects of corticosteroids in two different contexts: higher dose *vs* usual care in adults with COVID-19 and hypoxia; and lower dose dexamethasone in adults with influenza and hypoxia (UK only).

Favourable modulation of the immune response is considered one of the possible mechanisms by which corticosteroids might be beneficial in the treatment of severe acute respiratory coronavirus infections, including influenza, COVID-19, SARS and MERS. Common to severe cases of these infections is the presence of hypercytokinemia and the development of acute lung injury or acute respiratory distress syndrome (ARDS).[11-14](#_ENREF_11) Pathologically, diffuse alveolar damage is found in patients who die from these infections.[15](#_ENREF_15)

*Corticosteroids in influenza*

RECOVERY and other randomised trials have now demonstrated the benefit of corticosteroids in hypoxic COVID-19 patients.[16](#_ENREF_16),[17](#_ENREF_17) However, the potential role of corticosteroids in severe influenza remains uncertain, with differing practices and controversy. Whilst observational studies report higher mortality associated with the use of corticosteroids in severe influenza, these studies are prone to biases, with a major concern being confounding by indication (the propensity to use corticosteroids only in the more severe patients as a rescue therapy).[18](#_ENREF_18) In practice, use of corticosteroids in severe influenza is variable and widespread.[19](#_ENREF_19) This therapeutic dilemma will only be resolved through an adequately powered randomised trial.

*Corticosteroids in COVID-19*

RECOVERY showed that dexamethasone at a dose of 6mg once daily for ten days or until discharge (whichever happens earliest) provided a significant reduction in mortality. Combining the IL-6 inhibitor tocilizumab with low dose dexamethasone resulted in a further reduction in mortality. This raises the question whether simply increasing the dose of corticosteroid could confer a similar clinical benefit to that of adding tocilizumab, but at substantially lower cost. Of note, even with dexamethasone 6mg and tocilizumab, mortality remained high at 29%. Although other randomised clinical trials in critically ill COVID-19 patients have used higher doses of dexamethasone (20mg once daily for five days followed by 10mg once daily for a further five days) and reported clinical benefit, these doses have not been compared with the lower dose used in RECOVERY. There is, therefore, uncertainty regarding the optimal dose of corticosteroids in moderate to severe COVID-19.Uncertainty remains about whether higher doses of corticosteroids may provide additional benefit in adults with hypoxia hospitalised with COVID-19.

Unlike lower doses, higher doses (>15mg dexamethasone) would completely saturate cytosolic glucocorticoid receptors and have enhanced non-genomic effects. In conditions where rapid control of inflammatory processes are required, short-term, high to very high doses of corticosteroids are used e.g.

* Sepsis dexamethasone 7.5 - 15mg equivalent daily[20](#_ENREF_20)
* ARDS: dexamethasone 20mg for five days followed by 10mg for five days[21](#_ENREF_21)
* Bacterial meningitis: dexamethasone 40mg daily for four days[22](#_ENREF_22)
* Tuberculous Meningitis dexamethasone 0.4mg/kg/day for 7 days then reducing over 8 weeks.[23](#_ENREF_23)
* Rheumatoid arthritis flare: dexamethasone 120mg pulse therapy.[24](#_ENREF_24)
* Community acquired pneumonia: dexamethasone 0.6mg/day for 2 days and methyl prednisolone 200mg /day then 80mg /day for 10 days.[25](#_ENREF_25)

**Empagliflozin:** Sodium glucose co-transporter 2 inhibitors (SGLT-2i) decrease glucose and insulin levels, and shift energy metabolism to an increased reliance on lipid oxidation, with a reduced reliance on glucose, and inhibition of glycolysis.[26](#_ENREF_26) This mechanism may be particularly important in COVID-19, as SARS-CoV-2 may depend on the glycolytic pathway for its replication, stimulating lipogenesis, which appears to be one of the key drivers of cellular damage.[27](#_ENREF_27),[28](#_ENREF_28) SGLT-2i rapidly improve endothelial function, possibly because of reduced oxidative stress.[29](#_ENREF_29) SGLT-2i have significant anti-inflammatory effects, reducing levels of C-reactive protein and interleukin-6.[30](#_ENREF_30) Experimental studies have also shown reduced activation of the NLRP3 inflammasome.[31](#_ENREF_31) SGLT-2i increase erythropoiesis resulting in increased haematocrit,[32](#_ENREF_32),[33](#_ENREF_33) and together with improved endothelial function[29](#_ENREF_29) may improve oxygen delivery to tissues. Moreover, SGLT-2i result in reduced extracellular volume in patients with fluid overload,[34](#_ENREF_34),[35](#_ENREF_35) and appear to reduce pulmonary artery pressure in patients with heart failure rapidly,[36](#_ENREF_36) leading to haemodynamic decongestion. Thus, SGLT-2i may favourably affect multiple processes, including but not limited to energy metabolism, endothelial function, oxidative stress, inflammation and autophagy, which are dysregulated during a major acute illness such as COVID-19. The DARE-19 trial compared dapagliflozin 10 mg with placebo for 30 days among 1250 patients admitted to hospital with COVID-19 who had mild hypoxia (SpO2 ≥94% on ≤5 L/min oxygen) and at least one risk factor (hypertension, type 2 diabetes mellitus, atherosclerotic cardiovascular disease, heart failure or chronic kidney disease).[37](#_ENREF_37) The treatment was well tolerated (11% discontinued prematurely with similar proportion in treatment and placebo group). The hazard ratio for the co-primary outcome of organ failure (non-invasive or invasive ventilation, requirement for cardiovascular support or new/worsened heart failure, doubling of creatinine or dialysis) or death was 0.80 (95% CI 0.58-1.10; 70 *vs* 86 events).[38](#_ENREF_38) Although this trial lacked statistical sensitivity, it supports the rationale for a larger trial.

**Sotrovimab [UK only]:** Sotrovimab (VIR-7831) is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike glycoprotein receptor binding domain. It was identified by screening antibodies from a patient who had been infected during the 2003 SARS-CoV-1 outbreak, and its ability to also neutralise SARS-CoV-2 implies that its binding site is highly conserved, maybe meaning mutational escape will be difficult.[39](#_ENREF_39) The Fc portion of the parent antibody has been modified to extend sotrovimab’s half-life to around 49 days. It is given as a single intravenous dose and been well tolerated in clinical studies, although occasional serious hypersensitivity reactions have occurred.

It is licenced in the UK for the treatment of COVID-19 in patients who do not require oxygen and are at high risk of developing severe disease (at a 500 mg dose). The COMET-ICE trial, conducted in 583 such patients, showed that when given within five days of symptom onset it reduced the risk of hospitalisation by 85%, from 7% in the control group to 1% in the sotrovimab group.[40](#_ENREF_40) Evidence in hospitalised patients is limited, and the sotrovimab arm of ACTIV-3 was stopped due to futility after recruiting 344 participants, although no safety concerns were raised.[41](#_ENREF_41) However, by recruiting around 10,000 patients, RECOVERY subsequently showed that another neutralising monoclonal antibody treatment (casirivimab+imdevimab) reduced mortality by 20% in hospitalised patients who were anti-spike antibody negative at baseline.

The Omicron SARS-CoV-2 variant that emerged in late 2021 has multiple spike protein mutations, which have led to its rapid expansion in immune populations. These also appear to cause near complete loss of neutralising activity by the monoclonal antibodies in casirivimab+imdevimab,[42](#_ENREF_42) and reduce the neutralising activity of Sotrovimab about 10-fold.[43](#_ENREF_43),[44](#_ENREF_44) Data comparing the peak and day 29 concentrations following 2.4 g casirivimab+imdevimab and 500 mg Sotrovimab demonstrate much lower concentrations of Sotrovimab.[45](#_ENREF_45) These pharmacodynamics and pharmacokinetic considerations underly the selection of a 1000 mg dose in this trial. The published safety of Sotrovimab and higher doses of other anti-spike human monoclonal antibodies (including the 8g dose of casirivimab+imdevimab used in RECOVERY) do not suggest a safety concern with this increased dose.

**Molnupiravir [UK only]:** Molnupiravir is a prodrug of the ribonucloside analogue N-hydroxycytidine (NHC), being rapidly converted into this form in plasma after absorption. NHC is then converted into the active triphosphate form in host cells by endogenous kinases. The SARS-CoV-2 viral RNA polymerase incorporates this into nascent viral RNA, resulting in copying errors that accumulate every replication cycle, ultimately preventing replication by a mechanism known as error catastrophe. This molecular target is conserved between Coronaviruses, and appears to have a high genetic barrier to resistance.[46](#_ENREF_46) Molnupiravir is given orally and has been well tolerated in clinical studies so far, with infrequent reports of gastrointestinal and allergic reactions.

Molnupiravir is licensed in the United Kingdom for the treatment of mild-moderate COVID-19 within 5 days of symptom onset. In the MOVe-OUT trial of 1433 such patients it reduced the risk of hospitalisation or death by 30%, from 9.7% in the placebo group to 6.8% in molnupiravir group.[47](#_ENREF_47) Evidence in hospitalised patients is limited, and the MOVe-IN trial randomised patients 1:1:1:1 to placebo vs. molnupiravir at 3 different doses (200mg, 400mg, 800mg). This study was abandoned after recruiting 304 inpatients as the manufacturer decided it was unlikely to demonstrate clinical benefit, although no safety concerns were raised.[48](#_ENREF_48) However, the study was underpowered to identify moderate but important benefits in hospitalised patients, so a larger trial is needed.

**Paxlovid [UK only]:** Paxlovid is a combination of PF-07321332 (nirmatrelvir) and ritonavir. Nirmatrelvir is a 3-chymotrypsin-like protease inhibitor which inhibits cleavage of polyproteins involved in viral replication.[49](#_ENREF_49" \o "Owen, 2021 #3143) It is packaged with ritonavir which inhibits its CYP3A-dependent metabolism and hence increases the plasma concentration of nirmatrelvir. It is approved in the UK for the treatment of adults with COVID-19 who do not require supplemental oxygen and are at increased risk of progression to severe COVID-19.[50](#_ENREF_50" \o "Medicines and Healthcare products Regulatory Agency, 2021 #3146)

Its approval is based on the interim analysis of the EPIC-HR trial in which 2246 participants with COVID-19 (symptom onset ≤5 days previously) were randomised to receive Paxlovid (300/100 mg) or placebo twice daily for 5 days. The primary outcome is the proportion of participants with COVID-19 related hospitalisation or death within 28 days of randomisation. In the interim analysis, 8/1037 (0.8%) allocated Paxlovid *vs* 66/1046 (6.3%) allocated placebo.[51](#_ENREF_51" \o "Food and Drug Administration, 2021 #3147) In an interim analysis of 774 participants, adverse events were similar between the two groups: 19% among those allocated Paxlovid *vs* 21% among those allocated placebo. Most were mild; only 1.7% *vs* 6.6% were serious and 2.1% *vs* 4.1% led to discontinuation.[52](#_ENREF_52" \o "Pfizer, 2021 #3145) SARS-CoV-2 main protease polymorphisms associated with reduced sensitivity to nirmatrelvir have been identified.[51](#_ENREF_51" \o "Food and Drug Administration, 2021 #3147) Their frequency and clinical significance is not yet known. Cross-resistance between nirmatrelvir and anti-SARS-CoV-2 monoclonal antibodies, molnupiravir or remdesivir are not expected given their different mechanisms of action.

**Baloxavir marboxil [UK only]:** Baloxavir marboxil is a cap-dependent endonuclease (CEN) inhibitor. CEN is an influenza virus-specific enzyme in the polymerase acidic subunit of the viral RNA polymerase complex. Through its action on CEN, baloxavir inhibits the transcription of influenza virus genomes resulting in inhibition of influenza A and B virus replication. It is approved in the USA, Japan, Australia, Europe, and the United Kingdom for the treatment of uncomplicated influenza and for post-exposure prophylaxis in individuals aged 12 years and older. Baloxavir is given in 2 oral doses (on day 1 and day 4) and is well tolerated, with allergic reactions being the only reported adverse reactions.

Baloxavir is not approved for the treatment of complicated influenza. A phase III placebo-controlled trial of baloxavir in adults hospitalised with severe influenza (Flagstone NCT03684044) did not find a significant reduction in the primary endpoint of time to clinical improvement (personal communication, Roche). However, time to clinical improvement, time to clinical response, influenza related complications, mortality, and time to cessation of viral shedding were all in favour of baloxavir. Fewer adverse events were observed in the baloxavir arm than in the standard of care arm. The Flagstone trial was small, comparing 214 subjects who received baloxavir with 125 who received usual care alone, and a larger study is need to determine whether baloxavir has modest but clinically relevant benefit in patients hospitalised with influenza.

**Oseltamivir [UK only]:**

The neuraminidase inhibitors (oseltamivir and zanamivir) are influenza specific antivirals that have been shown in randomised controlled trials to improve outcomes in uncomplicated influenza and to be effective as post-exposure prophylaxis. They have not, however, been shown to be effective in patients hospitalised with severe influenza. Although observational studies have reported clinical benefit in patients hospitalised with severe influenza, there are no randomised controlled trial data. Consequently, the use of neuraminidase inhibitors in this patient population is variable. A randomised controlled trial of neuraminidase inhibitors in patients hospitalised with severe influenza has been recommended by an expert group convened by the Academy of Medical Sciences and the Wellcome Trust, and most clincians would welcome such a trial.[53](#_ENREF_53),[54](#_ENREF_54) The duration of treatment (5 days, or 10 days if the patient is immunosuppressed in the opinion of the managing clinician) is the same as that used in clinical practice and in the Summary of Product Characteristics.

## Appendix 2: Drug specific contraindications and cautions

**Corticosteroid**

Contraindications:

* Known contra-indication to short-term corticosteroid.
* Patients with suspected or confirmed influenza co-infection are not eligible for the high-dose dexamethasone comparision for COVID-19 (Randomisation part E).
* Patients in the UK with suspected or confirmed SARS-CoV-2 co-infection are not eligible for the low-dose dexamethasone comparison for influenza infection because of the proven benefits of dexamethasone in COVID-19 (Randomisation part I).
* Patients eligible for the Paxlovid comparison (Randomisation part L) will be excluded by the randomisation system from the high-dose dexamethasone comparison for COVID-19 (Randomisation part E) in view of the potential interaction between Paxlovid and dexamethasone.
* Current use of Paxlovid, ritonavir or other potent CYP3A inhibitors.

Cautions:

* Endemic infections may be screened for as required by local practice.
* Other immunomodulatory therapies are not contraindicated, but investigators should consider the total burden of therapy (eg, combining IL-6 receptor antagonist therapy with high-dose dexamethasone).

**Empagliflozin**

Contraindications:

* Type 1 diabetes mellitus (or post-pancreatectomy diabetes)
* Pregnancy and breast-feeding
* History of ketoacidosis
* Other patients with diabetes: blood ketones ≥1.5 mmol/L (or urine ketones ≥2+ if near-patient testing for blood ketones unavailable). Such patients are eligible once their ketosis has resolved.

Cautions:

* Participants with diabetes allocated empagliflozin should have regular checks of blood ketones (or urine ketones if blood ketone testing is unavailable)[[17]](#footnote-21). Blood ketones should be checked twice daily or urine ketones daily (or if clinical concern). If blood ketones rise ≥1.5 mmol/L (or urine ketones ≥2+), clinicians should:
  + Ensure adequate fluid and calorific intake
  + Consider increasing insulin dose (if on insulin)
  + Inform local diabetes team (if available) and treat ketosis using local protocols
  + Consider discontinuing empagliflozin until ketosis resolves
* Clinicians should consider temporarily discontinuing empagliflozin in participants with diabetes mellitus who cannot maintain oral calorific intake (until nutrition is restored)
* Clinicians should be aware of “euglycaemic ketoacidosis” which occurs with empagliflozin and should check ketones (ideally blood) if this is suspected (e.g. unexplained metabolic acidosis)
* Empagliflozin does not cause hypoglycaemia alone, but may do so in combination with insulin or insulin secretagogues. Doses of these other medications may need to be temporarily modified while the participant is taking empagliflozin
* Empagliflozin causes an osmotic diuresis so careful fluid balance assessment is required
* Empagliflozin increases the risk of mycotic genital infections (e.g. candidiasis) which are usually easily treated with topical therapy. It is unclear whether it causes Fournier’s gangrene (a very rare genital infection), but clinicians should be aware.

**Sotrovimab**

Contraindications:

* Weight <40kg (if <18 years old; no weight restriction for adults)
* Known hypersensitivity to sotrovimab or the drug product excipients

Cautions: no dose adjustment for kidney or liver function is required.

**Molnupiravir**

Contraindications:

* Age <18 years
* Pregnancy or breast-feeding. Women of child-bearing potential should be advised not to get pregnant while taking molnupiravir or for 4 days after completing the course
* Known hypersensitivity to molnupiravir or its excipients
* Prior treatment with molnupiravir during the index illness

Cautions: no dose adjustment for kidney or liver function is required.

**Paxlovid**

Contraindications:

* Age <18 years
* Severe hepatic impairment (Child-Pugh class C)
* Severe renal impairment (eGFR <30 mL/min/1.73m2)
* First trimester (i.e. first 12 weeks) of pregnancy
* Prior treatment with Paxlovid during the index illness
* Known hypersensitivity to nirmatrelvir (PF-07321332) or ritonavir (including hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption)
* Concomitant therapy with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious reactions.
  + α1-adrenoreceptor antagonist (afluzosin)
  + Analgesics (pethidine, piroxicam, propoxyphene)
  + Anti-anginal (ranolazine)
  + Anti-arrhythmics (amiodarone, bepridil, dronaderone, encainide, flecainide, propafenone, quinidine)
  + Antibacterials (fusidic acid)
  + Anticancer (neratinib, venetoclax)
  + Anti-gout (colchicine)
  + Antihistamine (astemizole, terfenadine)
  + Antipsychotics (lurasidone, pimozide, clozapine, quietiapine)
  + Ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine)
  + Gastrointestinal motility agent (cisapride)
  + Lipid modifying agents (lovastatin, simvastatin, lomitapide)
  + PDE5 inhibitors (avanafil, vardenafil, sildenafil)
  + Sedatives (clorazepate, diazepam, estazolam, flurazepam, triazolam, oral midazolam)
  + High-dose dexamethasone (>6 mg base once daily)
* Concomitant therapy with drugs that are potent CYP3A inducers (which may reduce plasma PF-07321332/ritonavir concentrations):
  + Anticancer (apalutamide)
  + Anticonvulsants (carbamazepine, phenobarbital, phenytoin)
  + Antimycobacterials (rifampicin)
  + Herbal products (St John’s Wort)

Cautions:

* Since ritonavir may decrease the efficacy of combined oral contraceptives, women using them should be advised to use effective alternative contraception or an additional barrier method until after one complete menstrual cycle after stopping.
* The necessity of using other drugs metabolised by CYP3A (or which induce or inhibit CYP3A) should be reviewed.[[18]](#footnote-22)
* Patients with moderate renal impairment (eGFR ≥30 <60 mL/min/1.73m2) should receive 150/100 mg twice daily (ie, one PF-07321332 tablet and one ritonavir tablet twice daily). Local pharmacists should remove one PF-07321332 tablet from each dose in the packet provided to the participant (see pharmacy manual at https://www.recoverytrial.net/for-site-staff/pharmacy for further detail).

Managing clinicians may consider if it is appropriate to temporarily withhold contraindicated concomitant medication while receiving Paxlovid or consider alternatives. The risks and benefits of doing so should be explained to the participant. Clear plans should be made about restarting such treatment and – if necessary – any checks that need to be made beforehand. These plans should be communicated to the participant and their general practitioner in the discharge summary.

**Baloxavir Marboxil**

Contraindications:

* Weight <40kg (regardless of age)
* Known hypersensitivity to baloxavir marboxil or the drug product excipients
* Participants who have received baloxavir marboxil for the current influenza infection

**Oseltamivir**

Contraindications:

* Known hypersensitivity to oseltamivir or the drug product excipients
* Participants who have received oseltamivir for the current influenza infection

Cautions:

* Dose should be reduced in presence of renal impairment
  + eGFR ≥30 mL/min/1.73m2: dose as in normal renal function (75 mg twice daily)
  + eGFR ≥10 <30 mL/min/1.73m2: 75 mg once daily
  + eGFR <10 mL/min/1.73m2: 75 mg as a single dose on day 1
* Dose should be reduced for adult patients weighing <40 kg to 60 mg twice daily

## Appendix 3: Paediatric dosing information

Children (aged <18 years old) will be recruited in the UK only.

**Randomisation of children with COVID-19 Pneumonia (Patients <12 years of age will NOT be eligible)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Arm** | **Route** | **Weight** | **Dose** |
| **No additional treatment** | - | - | - |
| **Sotrovimab** | Intravenous | Children <12 years old excluded | |
| <40 kg | Excluded regardless of age |
| ≥40 kg | 1000 mg intravenous in 100 mL of 0.9% NaCl or 5% dextrose over 1 hour |



**Influenza Randomisations**

|  |  |  |  |
| --- | --- | --- | --- |
| **Arm** | **Route** | **Weight/Age** | **Dose** |
| **Oseltamivir**   * 30, 45 and 75 mg capsules * Oral suspension a | Oral  or  Other enteral routes | Less than 36 weeks corrected gestational age | 1 mg/kg twice daily for 5 days b |
| 0 - 12 months (≥36 weeks corrected gestational age) | |  |  | | --- | --- | | Weight (kg) | Dose | | <10 | 3 mg/kg twice daily for 5 days b | | ≥ 10 | 30 mg twice daily for 5 days b | |
| ≥ 1 year | |  |  | | --- | --- | | Weight (kg) | Dose | | <10 | 3 mg/kg twice daily for 5 days b | | ≥ 10 to 15 | 30 mg twice daily for 5 days b | | > 15 to 23 | 45 mg twice daily for 5 days b | | > 23 to 40 | 60 mg twice daily for 5 days b | | > 40 | 75 mg twice daily for 5 days b |   Those within significant renal impairment (CrCl 10 - 30 mL/min) should receive once daily dosing. Those with CrCl <10 ml/min should receive only a single dose on day 1. |
| Baloxavir marboxil  - 20 and 40 mg tablets | Oral  or  Other enteral routes | ≥ 12 years old | |  |  | | --- | --- | | Weight (kg) | Dose | | <40 | Not eligible | | ≥40 < 80 | 40 mg on day 1 and day 4 | | ≥ 80 | 80 mg on day 1 and day 4 | |
| Low dose corticosteroids | Oral  or  Other enteral routes  or  Intravenous | Less than 36 weeks corrected gestational age | Hydrocortisone (IV)  0.5 mg/kg every 12 hours for 7 days and then 0.5mg/kg once daily for 3 days |
| ≥0 month (≥36 weeks corrected gestational age) | Dexamethasone:  150 micrograms/kg (as base) once daily (max: 6 mg once daily) for 10 days (or until discharge if sooner) |

a Public Health England advises that oseltamivir oral suspension should be reserved for children under the age of 1 year. Children over 1 year of age, those with swallowing difficulties, and those receiving nasogastric oseltamivir, should use capsules which can be opened and mixed into an appropriate sugary liquid.

b 10 days if immunocompromised

## Appendix 4: Use of IMPs in pregnant and breastfeeding women

All trial drugs (except empagliflozin, sotrovimab, molnupiravir, Paxlovid and baloxavir) have been used in pregnant women with pre-existing medical disorders where benefits outweigh the risks to fetus or woman, including in the first trimester. The existing data related to each drug is summarised below. The potential inclusion of any pregnant women should be discussed with a consultant obstetrician (or obstetric physician) and all consent discussions should be documented in the medical records.

**Corticosteroids**

Prednisolone or, in women unable to take oral medicine, hydrocortisone or methylprednisolone are recommended instead of dexamethasone treatment in light of accumulating evidence that repeated doses of dexamethasone have deleterious effects on long-term neurodevelopment of the fetus.[55-57](#_ENREF_55) While 90% dexamethasone is transferred transplacentally to the fetus, both hydrocortisone and prednisolone are converted by 11β-hydroxysteroid dehydrogenase to inactive glucocorticoids and considerably less drug is transferred to the fetus. Glucocorticoids can worsen maternal glycaemic control, so blood glucose should be checked and managed appropriately. Otherwise there is no convincing evidence that prednisolone use is associated with increased rates of adverse pregnancy outcomes when taken in the first trimester or later pregnancy.[58](#_ENREF_58) Very low concentrations of prednisolone enter breastmilk. There is a paucity of data about pharmacological use of hydrocortisone, but it is likely that this is also safe when breastfeeding,[58](#_ENREF_58) as also reviewed in the Lactmed database ([www.ncbi.nlm.nih.gov/books/NBK501076/](http://www.ncbi.nlm.nih.gov/books/NBK501076/)). Prednisolone (or hydrocortisone) should be used in breastfeeding women, in preference to dexamethasone.

**Empagliflozin**

Empagliflozin is not recommended for use in pregnant or breastfeeding women. Empagliflozin will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

**Sotrovimab**

There are no data from the use of sotrovimab in pregnant women. Since sotrovimab is a human immunoglobulin G animal studies have not been evaluated with respect to reproductive toxicity. No off-target binding was detected in a cross-reactive binding assay using a protein array enriched for human embryofetal proteins. Since sotrovimab is a human immunoglobulin G, it has the potential for placental transfer from the mother to the developing foetus. The potential treatment benefit or risk of placental transfer of sotrovimab to the developing foetus is not known. Sotrovimab may be used during pregnancy where the expected benefit to the mother justifies the risk to the foetus.

There are no data on the excretion of sotrovimab in human milk. The potential treatment benefit or risk to the newborn or infants via breastfeeding is not known. Decisions on whether to breastfeed during treatment or to abstain from sotrovimab therapy should take into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

**Molnupiravir**

Molnupiravir is not recommended for use in pregnant or breastfeeding women. Molnupiravir will only be included in the randomisation of women of child-bearing potential if they have had a negative pregnancy test since admission.

**Paxlovid**

Preclinical animal reproductive toxicity studies have not identified adverse effects on fetal morphology or embryo-fetal viability in rat or rabbit models with doses of nirmatrelvir up to 12 times the human dose (equivalence based on predicted AUC concentrations). The offspring of pregnant rabbits administered 24 times the equivalent human dose, lower fetal body weights were observed but evidence of maternal toxicity was described (impact on weight gain/food consumption).[52](#_ENREF_52" \o "Pfizer, 2021 #3145) There is a large amount of published evidence relating to the safety of ritonavir in human pregnancy, collected from antiretroviral and HIV/AIDS pregnancy registries. Overall, these data do not provide compelling evidence that ritonavir use in the first trimester is associated with an increased risk of malformation above the expected background rate of 2-3%. As Paxlovid has not previous been given to pregnant women, women in the first trimester of pregnancy will be excluded from this comparison.

**Baloxavir marboxil**

There are no data from the use of baloxavir marboxil in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. Baloxavir treatment may be of particular benefit to pregnant women with influenza, as they are at increased risk of developing severe disease. Preclinical animal models of exposure in pregnancy do not provide evidence of adverse embryo-fetal effects at doses up to five and seven times the human therapeutic dose respectively. The risk of harm from baloxavir in pregnancy is likely to be low given the animal model data, together with the therapeutic target for baloxavir being a virus specific enzyme. It is unknown whether baloxavir marboxil or baloxavir are excreted in human milk, and baloxivir may be considered.

**Oseltamivir**

There are observational data on the use of oseltamivir in pregnant women including >1000 women exposed during the first trimester. These studies found no evidence of adverse embryo-fetal effects. Oseltamivir is currently used in pregnant women. Its use may also be considered in breastfeeding women: it is excreted in breast milk but at low concentrations that would be subtherapeutic dose to the infant.

## Appendix 5: Organisational Structure and Responsibilities

**Chief Investigator**

The Chief Investigator has overall responsibility for:

1. Design and conduct of the Study in collaboration with the Trial Steering Committee;
2. Preparation of the Protocol and subsequent revisions.

**Trial Steering Committee**

The Trial Steering Committee (see below for list of members) is responsible for:

1. Agreement of the final Protocol and the Data Analysis Plans;
2. Reviewing progress of the study and, if necessary, deciding on Protocol changes;
3. Review and approval of study publications and substudy proposals;
4. Reviewing new studies that may be of relevance.

**International Steering Committee**

The International Steering Committee (see below for list of members) is responsible for:

1. Reviewing progress of the study in sites outside the UK;
2. Review of study publications and substudy proposals;
3. Considering potential new therapies to be included in sites outside the UK;
4. Assisting RCC in selection of LCCs;
5. Reviewing new studies that may be of relevance.

**Data Monitoring Committee**

The independent Data Monitoring Committee is responsible for:

1. Reviewing unblinded interim analyses according to the Protocol;
2. Advising the Steering Committee if, in their view, the randomised data provide evidence that may warrant a change in the Protocol (e.g. modification or cessation of one or more of the treatment arms).

**Central Coordinating Office (CCO)**

The CCO is responsible for the overall coordination of the Study, including:

1. Study planning and organisation of Steering Committee meetings;
2. Ensuring necessary regulatory and ethics committee approvals;
3. Development of Standard Operating Procedures and computer systems
4. Monitoring overall progress of the study;
5. Provision of study materials to RCCs/LCCs;
6. Monitoring and reporting safety information in line with the Protocol and regulatory requirements;
7. Dealing with technical, medical and administrative queries from LCCs.

**Regional Coordinating Centre (RCC)**

The RCCs are responsible for:

1. Ensuring necessary regulatory and ethics committee approvals;
2. Provision of study materials to LCCs;
3. Dealing with technical, medical and administrative queries from LCCs.

**Local Clinical Centres (LCC)**

The LCC lead investigator and LCC clinic staff are responsible for:

1. Obtaining all relevant local permissions (assisted by the CCO);
2. All trial activities at the LCC, including appropriate training and supervision for clinical staff;
3. Conducting trial procedures at the LCC in line with all relevant local policies and procedures;
4. Dealing with enquiries from participants and others.

**STEERING COMMITTEE**

(Major organisational and policy decisions, and scientific advice; blinded to treatment allocation)

|  |  |  |
| --- | --- | --- |
| Chief Investigator  Deputy Chief Investigator | Peter Horby  Martin Landray | |
| Clinical Trial Unit Lead | Richard Haynes | |
| Co-investigators | Kenneth Baillie (Scotland Lead), Maya Buch, Saul Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Marian Knight, Wei Shen Lim, Marion Mafham, Alan Montgomery, Aparna Mukherjee, Andrew Mumford, Kathy Rowan, Guy Thwaites, Jeremy Day | |
|  |  |

**International Committees**

*Asia*

Chair Do Van Dung

Regional Lead Investigators Guy Thwaites, Jeremy Day

Independent members: Vietnam : Nguyen Ngo Quang, Prof. Binh

Indonesia: Erlina Burhan, Bachti Alisjahbana

Nepal: Janak Koirala, Sudha Basnet

Other members: Evelyne Kestelyn, Buddha Basnyat, Pradip Gyanwali, Raph Hamers, Peter Horby

*Africa*

Chair TBC

Independent members: Ghana: TBD

South Africa: TBD

Other members: John Amuasi, Peter Horby, Jeremy Nel

**DATA MONITORING COMMITTEE**

(Interim analyses and response to specific concerns)

|  |  |
| --- | --- |
| Chair | Peter Sandercock |
| Members | Janet Darbyshire, David DeMets, Robert Fowler,  David Lalloo, Mohammed Munavvar, Adilia Warris, Janet Wittes |
| Statisticians (non-voting) | Jonathan Emberson, Natalie Staplin |

1. REFERENCES

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.

2. Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 2020;584:120-4.

3. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.

4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

5. Whittaker E, Bamford A, Kenny J, et al. Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. JAMA 2020.

6. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.

7. Moss JWE, Davidson C, Mattock R, Gibbons I, Mealing S, Carroll S. Quantifying the direct secondary health care cost of seasonal influenza in England. BMC public health 2020;20:1464.

8. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. Scandinavian Journal of Statistics 1979;6:65-70.

9. Venet D, Doffagne E, Burzykowski T, et al. A statistical approach to central monitoring of data quality in clinical trials. Clin Trials 2012;9:705-13.

10. Oversight of Clinical Investigations--A Risk-Based Approach to Monitoring. 2013. (Accessed 18 August 2017, at <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM269919.pdf>.)

11. Lau SKP, Lau CCY, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013;94:2679-90.

12. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006;12:1203-7.

13. Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13:3-10.

14. Short KR, Veeris R, Leijten LM, et al. Proinflammatory Cytokine Responses in Extra-Respiratory Tissues During Severe Influenza. J Infect Dis 2017;216:829-33.

15. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8:420-2.

16. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704.

17. W. H. O. Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA 2020;324:1330-41.

18. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med 2020;48:e98-e106.

19. Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antiviral Res 2018;150:202-16.

20. Rochwerg B, Oczkowski SJ, Siemieniuk RAC, et al. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. Crit Care Med 2018;46:1411-20.

21. Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med 2020;8:267-76.

22. Glimaker M, Brink M, Naucler P, Sjolin J. Betamethasone and dexamethasone in adult community-acquired bacterial meningitis: a quality registry study from 1995 to 2014. Clin Microbiol Infect 2016;22:814 e1- e7.

23. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-51.

24. Sadra V, Khabbazi A, Kolahi S, Hajialiloo M, Ghojazadeh M. Randomized double-blind study of the effect of dexamethasone and methylprednisolone pulse in the control of rheumatoid arthritis flare-up: a preliminary study. Int J Rheum Dis 2014;17:389-93.

25. van Woensel JB, van Aalderen WM, de Weerd W, et al. Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus. Thorax 2003;58:383-7.

26. Daniele G, Xiong J, Solis-Herrera C, et al. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care 2016;39:2036-41.

27. Codo AC, Davanzo GG, Monteiro LB, et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab 2020;32:437-46.e5.

28. Icard P, Lincet H, Wu Z, et al. The key role of Warburg effect in SARS-CoV-2 replication and associated inflammatory response. Biochimie 2021;180:169-77.

29. Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol 2017;16:138.

30. Bonnet F, Scheen AJ. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes & metabolism 2018;44:457-64.

31. Kim SR, Lee SG, Kim SH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 2020;11:2127.

32. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, obesity & metabolism 2013;15:853-62.

33. Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis. The Journal of clinical endocrinology and metabolism 2020;105.

34. Ohara K, Masuda T, Morinari M, et al. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease. Diabetol Metab Syndr 2020;12:37.

35. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. Circulation 2020;142:1028-39.

36. Mullens W, Martens P, Forouzan O, et al. Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 2020;7:2071-3.

37. Kosiborod M, Berwanger O, Koch GG, et al. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study. Diabetes, obesity & metabolism 2021;23:886-96.

38. Dapagliflozin in Respiratory Failure in Patients With COVID-19 - DARE-19. 2021. (Accessed 09-Jun-2021, at <https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/05/14/02/40/DARE-19>.)

39. Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020;583:290-5.

40. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med 2021;385:1941-50.

41. NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies. 2021. at <https://www.nih.gov/news-events/news-releases/nih-sponsored-activ-3-clinical-trial-closes-enrollment-into-two-sub-studies>.)

42. Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. MedRxiv 2021.

43. Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. BioRxiv 2021.

44. Cao YC, Wang Y, Jian F, et al. B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. BioRxiv 2021.

45. GlaxoSmithKline. Xevudy - summary of product characteristics2021.

46. Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-Molecule Antiviral beta-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol 2019;93.

47. Merck announces results from MOVe-OUT Study. 2021. at <https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnupiravir-an-investigational-oral-antiviral-medicine-in-at-risk-adults-with-mild-to-moderate-covid-19/>.)

48. Merck progress update. 2021. at <https://www.merck.com/news/merck-and-ridgeback-biotherapeutics-provide-update-on-progress-of-clinical-development-program-for-molnupiravir-an-investigational-oral-therapeutic-for-the-treatment-of-mild-to-moderate-covid-19/>.)

49. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374:1586-93.

50. Regulatory approval of Paxlovid. 2021. (Accessed 13-Jan-2022, at <https://www.gov.uk/government/publications/regulatory-approval-of-paxlovid>.)

51. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorisation for Paxlovid. 2021.

52. Pfizer. Summary of Product Characteristics for Paxlovid. 2021.

53. Bradbury N, Nguyen-Van-Tam J, Lim WS. Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza. BMC Health Services Research 2018;18:311.

54. Academy of Medical Sciences, Wellcome Trust. Use of Neuraminidase Inhibitors in Influenza. 2015.

55. Tam EW, Chau V, Ferriero DM, et al. Preterm cerebellar growth impairment after postnatal exposure to glucocorticoids. Sci Transl Med 2011;3:105ra.

56. Newnham JP, Jobe AH. Should we be prescribing repeated courses of antenatal corticosteroids? Semin Fetal Neonatal Med 2009;14:157-63.

57. Chang YP. Evidence for adverse effect of perinatal glucocorticoid use on the developing brain. Korean J Pediatr 2014;57:101-9.

58. Flint J, Panchal S, Hurrell A, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-Part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford) 2016;55:1698-702.

1. Contact details

Website: [www.recoverytrial.net](http://www.recoverytrial.net)

(copies of this protocol and related forms and information can be downloaded)

**RECOVERY Central Coordinating Office:**

Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF

United Kingdom

Tel: +44 (0)800 1385451

E-mail: recoverytrial@ndph.ox.ac.uk

**RECOVERY Vietnam:**

Oxford University Clinical Research Unit, Centre for Tropical Medicine, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam

Tel: +84 8 39241983

E-mail: [recoverytrial@oucru.org](mailto:recoverytrial@ndph.ox.ac.uk)

**RECOVERY Indonesia:**

Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology

Jl. P. Diponegoro No. 69, Jakarta-Indonesia 10430

Tel: +62 21 31900971

**RECOVERY Nepal:**

Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal

Tel : +977 01 5522295

**RECOVERY Ghana:**

Kumasi Center for Collaborative Research in Tropical MedicineKNUST, Southend Asuogya Road, GPS: AK-312-1059, Kumasi, GhanaTel: +233 278 364 389

**RECOVERY South Africa:**

Wits Health Consortium, 31 Princess of Wales Terrace, Parktown, Johannesburg, South Africa

Tel: +27 11 274 9200

**RECOVERY Sri Lanka & Pakistan:**

National Intensive Care Surveillance - M.O.R.U, 2nd Floor, YMBA Building, Borella, Colombo 08, Sri Lanka

Tel: +94 114 063739

**RECOVERY India:**

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, Ramalingaswami Bhavan, Ansari Nagar, ICMR-110029

Tel: +91 996 840 8999

**To RANDOMISE a patient, visit:**

|  |
| --- |
| Website: [www.recoverytrial.net](http://www.recoverytrial.net) |

1. https://www.gov.uk/government/publications/covid-19-treatments-making-a-proposal-for-clinical-trials/guidance-making-a-proposal-for-covid-19-therapeutics-clinical-trials#uk-covid-19-therapeutics-advisory-panel-uk-ctap [↑](#footnote-ref-2)
2. Independent clinicians may complete study training, but have no other involvement in the trial, e.g. eligibility assessment, or randomisation [↑](#footnote-ref-4)
3. Unless required by local regulations. (This is not required in the UK.) [↑](#footnote-ref-5)
4. The witness should be impartial i.e. not a member of the research team, but they do not require specific training or knowledge of the trial. [↑](#footnote-ref-6)
5. A woman of childbearing potential is defined as a post-menarchal pre-menopausal female capable of becoming pregnant. This includes women on oral, injectable, or mechanical contraception; women who are single; women whose male partners have been vasectomized or whose male partners have received or are utilizing mechanical contraceptive devices. The potential inclusion of any pregnant women should be discussed with a consultant obstetrician (or obstetric physician). [↑](#footnote-ref-7)
6. Collection of these samples will continue until the Steering Committee determine (on the basis of data blinded to treatment allocation) that sufficient information is available to assess the effect of treatment on viral load and/or resistance markers. [↑](#footnote-ref-8)
7. Usual care in hypoxic patients is expected to include low dose (6mg daily) dexamethasone [↑](#footnote-ref-9)
8. Treatment should be discontinued at 10 days or on discharge from hospital if sooner. Participants can be given a short ‘weaning’ course when they complete their study allocation if considered clinically necessary. [↑](#footnote-ref-10)
9. Pregnant women should receive either prednisolone (130 mg) orally or hydrocortisone (540 mg in divided doses) intravenously or methylprednisolone (100 mg) intravenously for five days, followed by either prednisolone (65 mg) orally or hydrocortisone (270 mg in divided doses) intravenously or methylprednisolone (50 mg) intravenously for five days. [↑](#footnote-ref-11)
10. If participant is discharged before course is complete, the participant should be provided with medication to complete the course at home. [↑](#footnote-ref-12)
11. Course can be extended to 10 days for immunosuppressed patients at the managing clinician’s discretion. [↑](#footnote-ref-13)
12. In pregnancy or breastfeeding women, prednisolone 40 mg administered by mouth (or intravenous hydrocortisone 80 mg twice daily) should be used instead of dexamethasone. For dosing in children see Appendix 3. [↑](#footnote-ref-14)
13. Available at https://www.recoverytrial.net/files/recovery-outcomes-definitions-v3-0.pdf [↑](#footnote-ref-16)
14. Collection of these samples will continue until the Steering Committee determine (on the basis of data blinded to treatment allocation) that sufficient information is available to assess the effect of treatment on viral load and/or resistance markers. Participants discharged before day 5 will be asked to take this sample at home and will be provided with instructions and materials to do so. [↑](#footnote-ref-17)
15. Serious Adverse Events are defined as those adverse events that result in death; are life-threatening; require in-patient hospitalisation or prolongation of existing hospitalisation; result in persistent or significant disability or incapacity; result in congenital anomaly or birth defect; or are important medical events in the opinion of the responsible investigator (that is, not life-threatening or resulting in hospitalisation, but may jeopardise the participant or require intervention to prevent one or other of the outcomes listed above). [↑](#footnote-ref-18)
16. Outside the UK, additional serious adverse event information (event description, date of onset, outcome, relatedness to study treatment) will be collected if required by national regulations. This will be collected on a web-based case report form and any forms required by local regulations. [↑](#footnote-ref-19)
17. These are near-patient tests and no sample will be retained for research purposes. [↑](#footnote-ref-21)
18. A list is available at <https://www.covid19-druginteractions.org/>. Please note these lists may not be exhaustive. [↑](#footnote-ref-22)